Biopharma Venture Capital In Europe: Still Alive, And Starting To Wake Up
This article was originally published in Start Up
Executive Summary
European VC is enjoying a revival -- of sorts. It was badly hit by the financial crisis, but now attractively low valuations, plus a continuing stream of opportunities, including Big Pharma spin-outs, are starting to lure some investors back, and provide validation for stalwarts who remained committed during the lean times.
You may also be interested in...
The A-List: The Trend-Shaping Series A Financings Of 2011
The capital drought that hit life science companies the past three years worked its way upstream in 2011, as several venture firms said they wouldn’t either continue in the life sciences or raise new funds. But our annual tally of life science Series A rounds presents a surprising twist: Series A rounds are up, not in blockbuster numbers by any stretch, but the downward trend of the recession years has finally been reversed. Among the year's nearly 100 Series A rounds we found plenty of oncology and peripheral vascular disease start-ups, as well as big bets on rare disease, along with some considerable nods to emerging markets.
New GSK Spin-Out Targets Hearing Loss
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.
New GSK Spin-Out Targets Hearing Loss
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.